VivoSeq
Infectious Disease

Meningioma

48

Pipeline Programs↗

25

Active Trials↗

23

Companies Involved↗

Meningioma is a moderately active landscape with 48 programs across 23 companies. The most active players are Javier Villaneuva-Meyer, MD, EMD Serono, Bristol-Myers Squibb. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

22/100

Mech. Concentration

9/100

Completion Rate

85/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Javier Villaneuva-Meyer, MD

1 program

Phase 1EMD Serono logo

EMD Serono

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2S

Shanghai Runshi Pharmaceutical Technology Co., Ltd

2 programs

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

39 of 49 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody612%Peptide24%Protein / enzyme12%Radiopharmaceutical12%

Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 96% of 55 pipeline programs.

Analysis

Trial Status

57

clinical trials

Completed22 · 39%
Recruiting17 · 30%
Unknown status6 · 11%
Active, not recruiting6 · 11%
Terminated3 · 5%
Not yet recruiting2 · 4%
Other1 · 2%

Clinical Trials

Trial Activity

57 trials

Cabozantinib for Patients With Recurrent or Progressive Meningioma
Recruiting·BBaptist Health South Florida·Phase 2·NCT05425004·24 enrolled
NEO100 and High-Grade Meningioma
Recruiting·NNeonc Technologies, Inc.·Phase 2·NCT05023018·30 enrolled
Abemaciclib in Newly Diagnosed Meningioma Patients
Recruiting·—·Phase 2·NCT05940493·72 enrolled
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Recruiting·MMayo Clinic·Phase 2·NCT04082520·41 enrolled
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
Recruiting·—·Phase 2·NCT04659811·37 enrolled
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
Recruiting·AAssistance Publique Hopitaux De Marseille·Phase 1·NCT03631953·25 enrolled
Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)
Recruiting·IIstituto Oncologico Veneto IRCCS·Phase 2·NCT06275919·104 enrolled
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
Recruiting·—·N/A·NCT04501705·29 enrolled
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
Recruiting·RTOG Foundation, Inc.·Phase 2·NCT06955169·153 enrolled
177Lu-DOTATATE for Recurrent Meningioma
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT06326190·136 enrolled
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
Recruiting·—·Phase 2·NCT06684795·40 enrolled
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1/2·NCT04997317·18 enrolled
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Recruiting·NNorthwestern University·Phase 2·NCT02847559·27 enrolled
A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Recruiting·EExelixis·Phase 2·NCT07428616·100 enrolled
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Recruiting·—·Phase 1·NCT07493447·30 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)